Quality of Vision questionnaire is comprehensive

Article

The Quality of Vision (QoV) questionnaire enables the comprehensive assessment of the subjective vision quality, claims a study in the journal Optometry and Vision Science.

The Quality of Vision (QoV) questionnaire enables the comprehensive assessment of the subjective vision quality, claims a study in the journal Optometry and Vision Science.

The group managed by Dr Colm McAlinden, School of Medicine, Flinders Medical Centre and Flinders University, Adelaide, South Australia, Australia, gathered data from four studies giving a total of 1930 completed questionnaires. The patient groups included spectacle wearers, contact lens wearers, post-laser refractive surgery, cataract patients and patients who underwent lens implantation surgery.

Three subscales of the questionnaire, frequency, severity and bothersome, were used in conjunction with the Bland-Altman limits of agreement (LoA) to assess interchangeability.

Mean difference, standard deviation of the differences, and the LoA for the frequency compared to the severity subscale were 2.8570, 6.784 and -10.4397 to 16.1537, respectively.

Mean difference, standard deviation and the LoA for frequency compared to bothersome were 5.4674, 12.5768 and -19.1831 to 30.1179, respectively. For the severity compared to the bothersome subscale these values were 2.6104, 9.4444 and -15.9006 to 21.1213, respectively.

The three subscales of the QoV questionnaire were useful for measuring different aspects of quality of vision. Practitioners should use all three subscales of the questionnaire to achieve the most comprehensive results on quality of vision.

The abstract can be found here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.